Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

Rhea-AI Summary

Cullinan Oncology, Inc. (Nasdaq: CGEM) announces its participation in the Stifel 2023 Targeted Oncology Days on April 26, 2023, at 2:30 PM EDT. The event will feature a fireside chat with CEO Nadim Ahmed, focusing on the company's innovative approaches to cancer therapies. A live webcast will be available on the investor relations website.

Cullinan Oncology is a biopharmaceutical firm committed to developing new cancer treatment standards. The company leverages extensive research in immuno-oncology and translational cancer medicine, aiming to create groundbreaking therapies through its diverse pipeline. They seek to activate the immune system or target oncogenic drivers, positioning their assets for potential market leadership in various cancer indications.

CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will participate in a fireside chat at the Stifel 2023 Targeted Oncology Days on April 26, 2023, at 2:30 PM EDT.

A live webcast of the fireside chat will be available via the Events section of the Company’s investor relations website at https://investors.cullinanoncology.com/events.

Investors interested in scheduling a one-on-one meeting with Cullinan Oncology’s management should contact their Stifel representative.

About Cullinan Oncology
Cullinan Oncology, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners. Anchored in a deep understanding of immuno-oncology and translational cancer medicine, we leverage our scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across cancer indications. Powered by our novel research model, we push conventional boundaries from candidate selection to cancer therapeutic, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. As a result, our diversified pipeline is strategically built with assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be the best or first in their class.

Our people possess deep scientific expertise, seek innovation openly, and exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients with cancer. Learn more about our Company at www.cullinanoncology.com, and follow us on LinkedIn and Twitter.

Contacts:
Investor Relations
Chad Messer
+1 203.464.8900
cmesser@cullinanoncology.com

Media
Rose Weldon
+1 215.801.7644
rweldon@cullinanoncology.com

FAQ

What is Cullinan Oncology's upcoming event on April 26, 2023?

Cullinan Oncology will participate in the Stifel 2023 Targeted Oncology Days, featuring a fireside chat with CEO Nadim Ahmed at 2:30 PM EDT.

Where can I watch the Cullinan Oncology fireside chat live?

The fireside chat will be available via the webcast on Cullinan Oncology's investor relations website.

What is the focus of Cullinan Oncology?

Cullinan Oncology focuses on developing modality-agnostic targeted oncology therapies to set new standards of care for cancer treatment.

What is the ticker symbol for Cullinan Oncology?

The ticker symbol for Cullinan Oncology is CGEM.

How does Cullinan Oncology approach cancer therapy development?

Cullinan Oncology employs a novel research model, emphasizing early experimentation and leveraging scientific expertise to fast-track promising cancer therapies.